Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gametocyte surface protein P230 (Pfs230) is a large, 363 kDa protein expressed on the surface of Plasmodium falciparum gametocytes and gametes [1, 12]. It belongs to the 6-Cys protein family and plays a vital role in the sexual stage of the parasite's life cycle, specifically in gamete fertilization and fusion within the mosquito midgut [1, 10]. Domain 1 (Pfs230D1) is the N-terminal-most 6-Cys domain and has been identified as the primary target for transmission-blocking vaccines (TBVs) due to its ability to elicit potent functional antibodies [3, 12, 13]. These antibodies interrupt the malaria transmission cycle by preventing the development of the parasite in the mosquito vector, often through complement-mediated lysis of gametes or steric hindrance of essential protein-protein interactions [2, 3, 16]. Pfs230D1-based vaccines, such as Pfs230D1-EPA, are currently in clinical trials and represent a key component of global malaria elimination and eradication efforts [3, 12]. The protein is anchored to the gamete membrane through interactions with Pfs48/45, forming a complex that is essential for establishing mosquito infection [12, 16]. Targeting this domain aims to achieve herd immunity by reducing the infectious reservoir in human populations [3, 4]. Challenges in vaccine development include the requirement for proper folding of its cysteine-rich structure and the need for adjuvants to enhance the durability of the immune response [2, 5, 12].
Induction of transmission-blocking antibodies that inhibit parasite development in the mosquito midgut through complement-mediated lysis of gametes and steric hindrance of gamete fusion.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gametocyte surface protein P230 domain 1 (Pfs230D1) (Pfs230D1).